Chronic Lymphoid Leukemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in adults. It is a slow-growing cancer of B-lymphocytes (a type of white blood cell) that originates in the bone marrow and spreads to the blood and lymph nodes. Unlike acute leukemias, many people with CLL live for years or even decades without needing immediate treatment.
When You Should Consider CLL Treatment
Extreme fatigue, drenching night sweats, or unexplained weight loss.
Massive or painful swelling of the spleen or lymph nodes.
Worsening anemia (low red cells) or thrombocytopenia (low platelets) indicating bone marrow failure.
Rapid lymphocyte doubling, where the white blood cell count doubles in less than 6 months.
Methods of CLL Management
Active Surveillance (Watch and Wait): The standard of care for early-stage, asymptomatic patients where starting chemotherapy early has not shown to increase lifespan.
BTK Inhibitors: Daily oral pills, such as Ibrutinib, Acalabrutinib, or Zanubrutinib, that block survival signals in B-cells.
BCL-2 Inhibitors: Targeted drugs like Venetoclax that trigger "cell death" in leukemia cells.
Monoclonal Antibodies: IV treatments like Obinutuzumab or Rituximab that "tag" cancer cells for the immune system to destroy.
IVIG Infusions: Regular immunoglobulin infusions to manage high infection risks for pneumonia or shingles.
How CLL Is Monitored
Regular Testing: Patients typically undergo blood tests and physical exams every 3 to 6 months.
Disease Progression Checks: Doctors monitor for signs of "active disease" that would necessitate a shift from surveillance to therapy.
Immune System Screening: Watching for autoimmune issues where the body attacks its own red blood cells (AIHA) or platelets (ITP).
Transformation Monitoring: Screening for Richter’s Transformation, where CLL evolves into an aggressive large B-cell lymphoma.
Pre-Procedure Preparation
Understanding the "Watch and Wait" approach and why immediate intervention is often avoided to prevent unnecessary side effects.
Comprehensive baseline blood work and physical assessments to establish a comparison for future monitoring.
Discussion of potential long-term risks, including a weakened immune system and increased infection susceptibility.
Evaluation of age and overall health, as the average age at diagnosis is 70.
Tests Before CLL Treatment
Complete Blood Count (CBC): To track white blood cell doubling time and levels of red cells and platelets.
Physical Examination: To check for organ issues like swelling of the spleen or lymph nodes.
Genetic Testing: To determine if specific mutations are present that might respond better to targeted oral therapies.
Clinical Trials Review: Assessment of trial data regarding the timing of treatment for stable patients.
Life After CLL Diagnosis
The overall 5-year survival rate for CLL is high, approximately 88%.
Many patients live for years or decades with the disease, eventually dying from causes unrelated to leukemia.
Patients must remain vigilant for complications like pneumonia, shingles, or the sudden onset of aggressive lymphoma.
Ongoing active surveillance remains the primary "lifestyle" for many early-stage patients.
Benefits of CLL Management
Avoids the toxicity and side effects of traditional chemotherapy through targeted oral therapies.
Provides a structured monitoring system to ensure treatment begins only when clinically necessary.
Utilizes modern medications that are more effective and less toxic than historical options.
Maintains a high quality of life for stable patients through the "Watch and Wait" strategy.
